Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Research holds promise for treatment of pediatric brain cancer

Research holds promise for treatment of pediatric brain cancer

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Antibody Screening Tools; Improving Workflows

Antibody Screening Tools; Improving Workflows

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

A Single Platform to Sequence All Monoclonal Antibody Proteins

A Single Platform to Sequence All Monoclonal Antibody Proteins

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

New approach to vaccine development and improved surveillance could help target deadly diseases

New approach to vaccine development and improved surveillance could help target deadly diseases

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Purifying Proteins from Mammalian Cell Culture

Purifying Proteins from Mammalian Cell Culture

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Neutrophil nanosponges provide hope for rheumatoid arthritis

Neutrophil nanosponges provide hope for rheumatoid arthritis

New project aims to combat drug-resistant bacteria in hospitals

New project aims to combat drug-resistant bacteria in hospitals

Sensitive, rapid slide agglutination assay to detect penicillin binding protein 2' in MRSA

Sensitive, rapid slide agglutination assay to detect penicillin binding protein 2' in MRSA